Literature DB >> 28167557

Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents.

María Ángeles Abengózar1, Rubén Cebrián2, José María Saugar1,3, Teresa Gárate3, Eva Valdivia2, Manuel Martínez-Bueno2, Mercedes Maqueda2, Luis Rivas4.   

Abstract

We report the feasibility of enterocin AS-48, a circular cationic peptide produced by Enterococcus faecalis, as a new leishmanicidal agent. AS-48 is lethal to Leishmania promastigotes as well as to axenic and intracellular amastigotes at low micromolar concentrations, with scarce cytotoxicity to macrophages. AS-48 induced a fast bioenergetic collapse of L. donovani promastigotes but only a partial permeation of their plasma membrane with limited entrance of vital dyes, even at concentrations beyond its full lethality. Fluoresceinated AS-48 was visualized inside parasites by confocal microscopy and seen to cause mitochondrial depolarization and reactive oxygen species production. Altogether, AS-48 appeared to have a mixed leishmanicidal mechanism that includes both plasma membrane permeabilization and additional intracellular targets, with mitochondrial dysfunctionality being of special relevance. This complex leishmanicidal mechanism of AS-48 persisted even for the killing of intracellular amastigotes, as evidenced by transmission electron microscopy. We demonstrated the potentiality of AS-48 as a new and safe leishmanicidal agent, expanding the growing repertoire of eukaryotic targets for bacteriocins, and our results provide a proof of mechanism for the search of new leishmanicidal bacteriocins, whose diversity constitutes an almost endless source for new structures at moderate production cost and whose safe use on food preservation is well established.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  antimicrobial peptide; bioenergetics; enterocin AS-48; intracellular parasite

Mesh:

Substances:

Year:  2017        PMID: 28167557      PMCID: PMC5365675          DOI: 10.1128/AAC.02288-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  71 in total

1.  Permeation of bacterial cells, permeation of cytoplasmic and artificial membrane vesicles, and channel formation on lipid bilayers by peptide antibiotic AS-48.

Authors:  A Gálvez; M Maqueda; M Martínez-Bueno; E Valdivia
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

Review 2.  Antineoplastic properties of bacteriocins: revisiting potential active agents.

Authors:  Gilbert Cornut; Claude Fortin; Denis Soulières
Journal:  Am J Clin Oncol       Date:  2008-08       Impact factor: 2.339

Review 3.  Trends in utilization of agro-industrial byproducts for production of bacteriocins and their biopreservative applications.

Authors:  Vandana Bali; Parmjit S Panesar; Manab B Bera
Journal:  Crit Rev Biotechnol       Date:  2014-11-28       Impact factor: 8.429

4.  An 'Upp'-turn in bacteriocin receptor identification.

Authors:  Paul D Cotter
Journal:  Mol Microbiol       Date:  2014-05-19       Impact factor: 3.501

Review 5.  Bacteriocins from lactic acid bacteria and their applications in meat and meat products.

Authors:  Weerapong Woraprayote; Yuwares Malila; Supaluk Sorapukdee; Adisorn Swetwiwathana; Soottawat Benjakul; Wonnop Visessanguan
Journal:  Meat Sci       Date:  2016-04-13       Impact factor: 5.209

6.  Effect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H.

Authors:  Maria Luisa Mangoni; Niv Papo; José M Saugar; Donatella Barra; Yechiel Shai; Maurizio Simmaco; Luis Rivas
Journal:  Biochemistry       Date:  2006-04-04       Impact factor: 3.162

7.  Effect of bacterial metabolites on microsporidian Nosema ceranae and on its host Apis mellifera.

Authors:  Martín P Porrini; M Carina Audisio; Daniela C Sabaté; Carolina Ibarguren; Sandra K Medici; Edgardo G Sarlo; P Melisa Garrido; Martín J Eguaras
Journal:  Parasitol Res       Date:  2010-05-14       Impact factor: 2.289

8.  Neutralizing antibodies against the peptide antibiotic AS-48: immunocytological studies.

Authors:  M Maqueda; A Gálvez; M Martínez-Bueno; I Guerra; E Valdivia
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

9.  A simple method for semi-preparative-scale production and recovery of enterocin AS-48 derived from Enterococcus faecalis subsp. liquefaciens A-48-32.

Authors:  Hikmate Abriouel; Eva Valdivia; Manuel Martínez-Bueno; Mercedes Maqueda; Antonio Gálvez
Journal:  J Microbiol Methods       Date:  2003-12       Impact factor: 2.363

10.  Antimycobacterial activity of bacteriocins and their complexes with liposomes.

Authors:  Vasily Sosunov; Vladimir Mischenko; Boris Eruslanov; Edward Svetoch; Yulia Shakina; Norman Stern; Konstantin Majorov; Galina Sorokoumova; Alla Selishcheva; Alexander Apt
Journal:  J Antimicrob Chemother       Date:  2007-03-08       Impact factor: 5.790

View more
  10 in total

1.  Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis.

Authors:  Clara Aguilar-Pérez; Begoña Gracia; Liliana Rodrigues; Asunción Vitoria; Rubén Cebrián; Nathalie Deboosère; Ok-Ryul Song; Priscille Brodin; Mercedes Maqueda; José A Aínsa
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

2.  Draft Genome Sequence of Enterococcus faecalis DD14, a Bacteriocinogenic Lactic Acid Bacterium with Anti-Clostridium Activity.

Authors:  Yanath Belguesmia; Valérie Leclère; Matthieu Duban; Eric Auclair; Djamel Drider
Journal:  Genome Announc       Date:  2017-07-27

Review 3.  The Genus Enterococcus: Between Probiotic Potential and Safety Concerns-An Update.

Authors:  Hasna Hanchi; Walid Mottawea; Khaled Sebei; Riadh Hammami
Journal:  Front Microbiol       Date:  2018-08-03       Impact factor: 5.640

Review 4.  Circular and Leaderless Bacteriocins: Biosynthesis, Mode of Action, Applications, and Prospects.

Authors:  Rodney H Perez; Takeshi Zendo; Kenji Sonomoto
Journal:  Front Microbiol       Date:  2018-09-04       Impact factor: 5.640

5.  Insights into Chagas treatment based on the potential of bacteriocin AS-48.

Authors:  Rubén Martín-Escolano; Rubén Cebrián; Javier Martín-Escolano; Maria J Rosales; Mercedes Maqueda; Manuel Sánchez-Moreno; Clotilde Marín
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-03-29       Impact factor: 4.077

6.  Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48.

Authors:  Marta Martínez-García; Jean-Mathieu Bart; Jenny Campos-Salinas; Eva Valdivia; Manuel Martínez-Bueno; Elena González-Rey; Miguel Navarro; Mercedes Maqueda; Rubén Cebrián; José M Pérez-Victoria
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-03-12       Impact factor: 4.077

7.  Control of Propionibacterium acnes by natural antimicrobial substances: Role of the bacteriocin AS-48 and lysozyme.

Authors:  Rubén Cebrián; Sergio Arévalo; Susana Rubiño; Salvador Arias-Santiago; María Dolores Rojo; Manuel Montalbán-López; Manuel Martínez-Bueno; Eva Valdivia; Mercedes Maqueda
Journal:  Sci Rep       Date:  2018-08-06       Impact factor: 4.379

Review 8.  Gut microbiota as a source of novel antimicrobials.

Authors:  Enriqueta Garcia-Gutierrez; Melinda J Mayer; Paul D Cotter; Arjan Narbad
Journal:  Gut Microbes       Date:  2018-05-22

9.  Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations.

Authors:  Samira Soltani; Riadh Hammami; Paul D Cotter; Sylvie Rebuffat; Laila Ben Said; Hélène Gaudreau; François Bédard; Eric Biron; Djamel Drider; Ismail Fliss
Journal:  FEMS Microbiol Rev       Date:  2021-01-08       Impact factor: 16.408

10.  Library of Selenocyanate and Diselenide Derivatives as In Vivo Antichagasic Compounds Targeting Trypanosoma cruzi Mitochondrion.

Authors:  Rubén Martín-Escolano; Daniel Molina-Carreño; Daniel Plano; Socorro Espuelas; María J Rosales; Esther Moreno; Carlos Aydillo; Carmen Sanmartín; Manuel Sánchez-Moreno; Clotilde Marín
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.